Concepts (235)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Transplantation Conditioning | 7 | 2016 | 2374 | 0.290 |
Why?
|
| Stem Cell Transplantation | 3 | 2017 | 1420 | 0.220 |
Why?
|
| Lymphoma, Mantle-Cell | 4 | 2013 | 750 | 0.220 |
Why?
|
| Ultrasonography | 13 | 2000 | 1932 | 0.200 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 4 | 2017 | 2488 | 0.190 |
Why?
|
| Antibodies, Monoclonal | 7 | 2012 | 4470 | 0.160 |
Why?
|
| Lymphoma, Follicular | 3 | 2012 | 636 | 0.150 |
Why?
|
| Candidiasis | 2 | 2000 | 278 | 0.150 |
Why?
|
| Lymphocyte Transfusion | 1 | 2017 | 174 | 0.130 |
Why?
|
| Bendamustine Hydrochloride | 1 | 2016 | 123 | 0.130 |
Why?
|
| Graft vs Host Disease | 5 | 2017 | 2811 | 0.130 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 7 | 2012 | 7055 | 0.120 |
Why?
|
| Thermography | 6 | 1977 | 57 | 0.120 |
Why?
|
| Thalidomide | 1 | 2017 | 597 | 0.110 |
Why?
|
| Lymphoma, Non-Hodgkin | 4 | 2003 | 1068 | 0.110 |
Why?
|
| SOXC Transcription Factors | 1 | 2013 | 58 | 0.110 |
Why?
|
| Rituximab | 7 | 2016 | 1594 | 0.100 |
Why?
|
| Lymphoma, T-Cell | 2 | 2007 | 367 | 0.100 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 6 | 2013 | 878 | 0.100 |
Why?
|
| Ki-67 Antigen | 1 | 2013 | 676 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2014 | 675 | 0.090 |
Why?
|
| Vidarabine | 3 | 2016 | 1384 | 0.090 |
Why?
|
| Myeloablative Agonists | 2 | 2012 | 388 | 0.090 |
Why?
|
| Chromosome Deletion | 1 | 2014 | 1057 | 0.080 |
Why?
|
| Disease-Free Survival | 9 | 2017 | 10268 | 0.080 |
Why?
|
| Antineoplastic Agents | 8 | 2009 | 14639 | 0.080 |
Why?
|
| Diphtheria Toxin | 2 | 2007 | 82 | 0.080 |
Why?
|
| Cyclophosphamide | 4 | 2016 | 3246 | 0.080 |
Why?
|
| Survival Rate | 9 | 2017 | 12535 | 0.070 |
Why?
|
| Lymphoma, B-Cell | 2 | 2004 | 930 | 0.070 |
Why?
|
| ZAP-70 Protein-Tyrosine Kinase | 1 | 2007 | 106 | 0.070 |
Why?
|
| Transplantation, Homologous | 6 | 2014 | 3048 | 0.070 |
Why?
|
| Graft vs Leukemia Effect | 1 | 2007 | 107 | 0.070 |
Why?
|
| Interleukin-2 | 2 | 2007 | 889 | 0.070 |
Why?
|
| Middle Aged | 29 | 2017 | 90570 | 0.060 |
Why?
|
| Aged | 23 | 2017 | 73641 | 0.060 |
Why?
|
| Adult | 26 | 2016 | 82074 | 0.060 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 6 | 2013 | 16752 | 0.060 |
Why?
|
| Porphyrias | 1 | 1984 | 1 | 0.060 |
Why?
|
| Tomography | 1 | 1984 | 63 | 0.060 |
Why?
|
| Computers | 1 | 1984 | 132 | 0.060 |
Why?
|
| Protease Inhibitors | 1 | 2004 | 207 | 0.060 |
Why?
|
| Dipeptidyl Peptidase 4 | 1 | 2003 | 56 | 0.050 |
Why?
|
| Pentostatin | 1 | 2003 | 121 | 0.050 |
Why?
|
| Female | 36 | 2017 | 148940 | 0.050 |
Why?
|
| Gallbladder | 1 | 1983 | 68 | 0.050 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2009 | 10409 | 0.050 |
Why?
|
| Cholecystitis | 1 | 1983 | 59 | 0.050 |
Why?
|
| Boronic Acids | 1 | 2004 | 355 | 0.050 |
Why?
|
| Follow-Up Studies | 7 | 2017 | 15280 | 0.050 |
Why?
|
| Male | 31 | 2017 | 128522 | 0.050 |
Why?
|
| Bile Ducts | 1 | 1983 | 115 | 0.050 |
Why?
|
| Parathyroid Neoplasms | 2 | 1975 | 189 | 0.050 |
Why?
|
| Liver | 2 | 2000 | 3061 | 0.050 |
Why?
|
| Pyrazines | 1 | 2004 | 511 | 0.050 |
Why?
|
| Humans | 46 | 2017 | 270809 | 0.050 |
Why?
|
| Remission Induction | 3 | 2013 | 3658 | 0.050 |
Why?
|
| Antineoplastic Agents, Phytogenic | 2 | 2002 | 898 | 0.050 |
Why?
|
| Acute Disease | 3 | 2017 | 2492 | 0.040 |
Why?
|
| Treatment Outcome | 11 | 2014 | 33860 | 0.040 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2003 | 741 | 0.040 |
Why?
|
| Camptothecin | 1 | 2002 | 540 | 0.040 |
Why?
|
| Recurrence | 4 | 2012 | 4878 | 0.040 |
Why?
|
| Combined Modality Therapy | 5 | 2013 | 9054 | 0.040 |
Why?
|
| Positron-Emission Tomography | 1 | 2008 | 2199 | 0.040 |
Why?
|
| Candida | 1 | 2000 | 171 | 0.040 |
Why?
|
| Drug Administration Schedule | 4 | 2007 | 3534 | 0.040 |
Why?
|
| Liver Diseases | 1 | 1984 | 601 | 0.040 |
Why?
|
| Spleen | 1 | 2000 | 719 | 0.040 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2008 | 1740 | 0.040 |
Why?
|
| Sonication | 1 | 1976 | 13 | 0.030 |
Why?
|
| Ovarian Neoplasms | 4 | 1978 | 4810 | 0.030 |
Why?
|
| Radiography | 3 | 2000 | 1998 | 0.030 |
Why?
|
| Transplantation, Autologous | 2 | 2013 | 2076 | 0.030 |
Why?
|
| Asparaginase | 1 | 1976 | 196 | 0.030 |
Why?
|
| Survival Analysis | 3 | 2014 | 9281 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 7 | 1999 | 7789 | 0.030 |
Why?
|
| Hyperparathyroidism | 2 | 1972 | 101 | 0.030 |
Why?
|
| Lung Diseases, Fungal | 1 | 1996 | 132 | 0.030 |
Why?
|
| Allografts | 1 | 2017 | 687 | 0.030 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 1996 | 189 | 0.030 |
Why?
|
| Antifungal Agents | 1 | 2000 | 882 | 0.030 |
Why?
|
| Lymphoma | 3 | 1999 | 1516 | 0.030 |
Why?
|
| Pancreatitis | 1 | 1976 | 296 | 0.030 |
Why?
|
| Prednisone | 1 | 1976 | 1034 | 0.030 |
Why?
|
| Adenoma | 2 | 1975 | 738 | 0.030 |
Why?
|
| Methods | 3 | 1978 | 221 | 0.030 |
Why?
|
| Radionuclide Imaging | 4 | 1987 | 654 | 0.030 |
Why?
|
| Parathyroid Diseases | 1 | 1972 | 17 | 0.030 |
Why?
|
| Synovial Cyst | 1 | 1991 | 7 | 0.020 |
Why?
|
| Cytarabine | 2 | 2013 | 2015 | 0.020 |
Why?
|
| Hip | 1 | 1991 | 26 | 0.020 |
Why?
|
| Radioimmunotherapy | 1 | 2012 | 128 | 0.020 |
Why?
|
| Thyroid Diseases | 1 | 1972 | 85 | 0.020 |
Why?
|
| Pelvis | 3 | 1999 | 383 | 0.020 |
Why?
|
| Urinary Tract Infections | 1 | 1996 | 347 | 0.020 |
Why?
|
| Infusions, Intravenous | 2 | 2005 | 1436 | 0.020 |
Why?
|
| Gastrointestinal Diseases | 1 | 1996 | 616 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 2003 | 3946 | 0.020 |
Why?
|
| Genital Neoplasms, Female | 1 | 1978 | 794 | 0.020 |
Why?
|
| Yttrium Radioisotopes | 1 | 2012 | 211 | 0.020 |
Why?
|
| Leukemia, Lymphoid | 2 | 1984 | 289 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2007 | 1623 | 0.020 |
Why?
|
| Time Factors | 3 | 2014 | 12979 | 0.020 |
Why?
|
| Referral and Consultation | 1 | 2014 | 930 | 0.020 |
Why?
|
| Feasibility Studies | 2 | 2009 | 2360 | 0.020 |
Why?
|
| Gallium Radioisotopes | 1 | 2008 | 62 | 0.020 |
Why?
|
| Transplantation Chimera | 1 | 2008 | 174 | 0.020 |
Why?
|
| Graft vs Tumor Effect | 1 | 2008 | 143 | 0.020 |
Why?
|
| Biomarkers, Tumor | 1 | 2007 | 10731 | 0.020 |
Why?
|
| Whole Body Imaging | 1 | 2008 | 120 | 0.020 |
Why?
|
| Adrenal Gland Diseases | 1 | 1987 | 70 | 0.020 |
Why?
|
| Adrenal Glands | 1 | 1987 | 131 | 0.020 |
Why?
|
| Transaminases | 1 | 2007 | 77 | 0.020 |
Why?
|
| 19-Iodocholesterol | 1 | 1986 | 1 | 0.020 |
Why?
|
| Mineralocorticoids | 1 | 1986 | 9 | 0.020 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2007 | 104 | 0.020 |
Why?
|
| Lumbosacral Plexus | 1 | 1986 | 15 | 0.020 |
Why?
|
| Biopsy, Needle | 2 | 2002 | 1381 | 0.020 |
Why?
|
| Peripheral Nervous System Neoplasms | 1 | 1986 | 72 | 0.020 |
Why?
|
| Retrospective Studies | 4 | 2014 | 39982 | 0.020 |
Why?
|
| Bone Neoplasms | 1 | 1998 | 2674 | 0.020 |
Why?
|
| Pelvic Neoplasms | 2 | 1978 | 200 | 0.020 |
Why?
|
| Models, Structural | 1 | 1984 | 94 | 0.020 |
Why?
|
| Liver Neoplasms | 2 | 1998 | 4843 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2007 | 984 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2003 | 5053 | 0.010 |
Why?
|
| Hypoalbuminemia | 1 | 2004 | 42 | 0.010 |
Why?
|
| Ganglioneuroma | 1 | 1984 | 44 | 0.010 |
Why?
|
| Receptors, Interleukin-2 | 1 | 2004 | 195 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2007 | 1308 | 0.010 |
Why?
|
| Breast Neoplasms | 4 | 1998 | 16246 | 0.010 |
Why?
|
| CD4 Antigens | 1 | 2004 | 170 | 0.010 |
Why?
|
| Thyroid Neoplasms | 2 | 1972 | 1908 | 0.010 |
Why?
|
| CD8 Antigens | 1 | 2004 | 174 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2013 | 6234 | 0.010 |
Why?
|
| Neoplasm Staging | 3 | 2007 | 14037 | 0.010 |
Why?
|
| Breast | 3 | 1988 | 1370 | 0.010 |
Why?
|
| Glycogen Storage Disease Type I | 1 | 1983 | 17 | 0.010 |
Why?
|
| Adrenal Cortex Neoplasms | 1 | 1986 | 242 | 0.010 |
Why?
|
| Bortezomib | 1 | 2004 | 551 | 0.010 |
Why?
|
| Cholesterol | 1 | 1986 | 656 | 0.010 |
Why?
|
| Goiter, Nodular | 2 | 1972 | 6 | 0.010 |
Why?
|
| Diaphragm | 1 | 1984 | 186 | 0.010 |
Why?
|
| Radiopharmaceuticals | 1 | 2008 | 1342 | 0.010 |
Why?
|
| Hyperparathyroidism, Secondary | 2 | 1972 | 19 | 0.010 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2008 | 1260 | 0.010 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 1986 | 407 | 0.010 |
Why?
|
| Hyperthyroidism | 2 | 1972 | 49 | 0.010 |
Why?
|
| B-Lymphocytes | 1 | 2008 | 1420 | 0.010 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 1984 | 296 | 0.010 |
Why?
|
| Aged, 80 and over | 3 | 2007 | 31117 | 0.010 |
Why?
|
| Administration, Oral | 1 | 2005 | 1592 | 0.010 |
Why?
|
| Vincristine | 1 | 2005 | 1583 | 0.010 |
Why?
|
| Infant | 2 | 1996 | 14003 | 0.010 |
Why?
|
| Topotecan | 1 | 2001 | 248 | 0.010 |
Why?
|
| Radiotherapy Dosage | 1 | 2009 | 4020 | 0.010 |
Why?
|
| Adolescent | 5 | 2008 | 32698 | 0.010 |
Why?
|
| Prognosis | 2 | 2009 | 22533 | 0.010 |
Why?
|
| Fatigue | 1 | 2007 | 1292 | 0.010 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2007 | 5417 | 0.010 |
Why?
|
| Dexamethasone | 1 | 2005 | 1525 | 0.010 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2009 | 6259 | 0.010 |
Why?
|
| Neoplasm Metastasis | 3 | 1986 | 5332 | 0.010 |
Why?
|
| Podophyllotoxin | 1 | 1999 | 66 | 0.010 |
Why?
|
| Carmustine | 1 | 1999 | 225 | 0.010 |
Why?
|
| Pulmonary Artery | 1 | 1983 | 520 | 0.010 |
Why?
|
| Maximum Tolerated Dose | 1 | 2002 | 1329 | 0.010 |
Why?
|
| Doxorubicin | 1 | 2005 | 3147 | 0.010 |
Why?
|
| Radiography, Abdominal | 1 | 1999 | 128 | 0.010 |
Why?
|
| Adenocarcinoma | 3 | 1983 | 7920 | 0.010 |
Why?
|
| Lung Diseases | 1 | 1983 | 750 | 0.010 |
Why?
|
| Blood Platelets | 1 | 2001 | 675 | 0.010 |
Why?
|
| Scrotum | 1 | 1977 | 59 | 0.010 |
Why?
|
| Neutrophils | 1 | 2001 | 855 | 0.010 |
Why?
|
| Carcinoma | 2 | 1986 | 2610 | 0.010 |
Why?
|
| Melphalan | 1 | 1999 | 879 | 0.010 |
Why?
|
| Histocompatibility Testing | 1 | 1998 | 488 | 0.010 |
Why?
|
| Age Factors | 1 | 2005 | 5443 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 1975 | 449 | 0.010 |
Why?
|
| Abdominal Neoplasms | 1 | 1977 | 251 | 0.010 |
Why?
|
| Patient Selection | 1 | 2002 | 2032 | 0.010 |
Why?
|
| Hypercalcemia | 1 | 1975 | 146 | 0.010 |
Why?
|
| Posture | 1 | 1975 | 206 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 1991 | 7923 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 2001 | 1944 | 0.010 |
Why?
|
| Paclitaxel | 1 | 2001 | 2114 | 0.010 |
Why?
|
| Uterine Neoplasms | 1 | 1978 | 578 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2008 | 13422 | 0.010 |
Why?
|
| Child | 6 | 1984 | 30572 | 0.010 |
Why?
|
| Diagnosis, Differential | 2 | 1984 | 4839 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2002 | 4396 | 0.010 |
Why?
|
| False Positive Reactions | 1 | 1972 | 374 | 0.010 |
Why?
|
| Risk Factors | 1 | 2009 | 17867 | 0.010 |
Why?
|
| Ethanol | 1 | 1972 | 271 | 0.010 |
Why?
|
| Hypothyroidism | 1 | 1972 | 207 | 0.010 |
Why?
|
| Cysts | 1 | 1972 | 206 | 0.010 |
Why?
|
| Incidence | 1 | 2000 | 5824 | 0.010 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 1983 | 5606 | 0.010 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 1983 | 2193 | 0.010 |
Why?
|
| Preoperative Care | 1 | 1975 | 1582 | 0.010 |
Why?
|
| Kidney Neoplasms | 1 | 1983 | 3116 | 0.000 |
Why?
|
| Adosterol | 1 | 1987 | 2 | 0.000 |
Why?
|
| Catecholamines | 1 | 1986 | 102 | 0.000 |
Why?
|
| Hyperaldosteronism | 1 | 1986 | 30 | 0.000 |
Why?
|
| Diabetic Neuropathies | 1 | 1986 | 93 | 0.000 |
Why?
|
| Retroperitoneal Space | 1 | 1984 | 156 | 0.000 |
Why?
|
| Steroids | 1 | 1986 | 372 | 0.000 |
Why?
|
| Iodine Radioisotopes | 1 | 1986 | 388 | 0.000 |
Why?
|
| False Negative Reactions | 1 | 1984 | 291 | 0.000 |
Why?
|
| Bronchography | 1 | 1983 | 24 | 0.000 |
Why?
|
| Pulmonary Atelectasis | 1 | 1983 | 51 | 0.000 |
Why?
|
| Postoperative Complications | 1 | 1978 | 5681 | 0.000 |
Why?
|
| Kidney Pelvis | 1 | 1983 | 113 | 0.000 |
Why?
|
| Pulmonary Emphysema | 1 | 1983 | 159 | 0.000 |
Why?
|
| Calcinosis | 1 | 1984 | 427 | 0.000 |
Why?
|
| Respiratory Insufficiency | 1 | 1984 | 343 | 0.000 |
Why?
|
| Carcinoma, Small Cell | 1 | 1983 | 426 | 0.000 |
Why?
|
| Pancreatic Neoplasms | 1 | 1977 | 5264 | 0.000 |
Why?
|
| Testicular Hydrocele | 1 | 1977 | 6 | 0.000 |
Why?
|
| Genital Diseases, Male | 1 | 1977 | 30 | 0.000 |
Why?
|
| Needles | 1 | 1977 | 107 | 0.000 |
Why?
|
| Xeroradiography | 1 | 1976 | 3 | 0.000 |
Why?
|
| Palpation | 1 | 1976 | 51 | 0.000 |
Why?
|
| Testicular Neoplasms | 1 | 1977 | 560 | 0.000 |
Why?
|
| Carcinoma in Situ | 1 | 1976 | 489 | 0.000 |
Why?
|
| Diagnostic Errors | 1 | 1976 | 518 | 0.000 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 1976 | 690 | 0.000 |
Why?
|
| Infant, Newborn | 1 | 1984 | 8607 | 0.000 |
Why?
|
| Mammography | 1 | 1976 | 1055 | 0.000 |
Why?
|
| Biopsy | 1 | 1976 | 3490 | 0.000 |
Why?
|
| Neoplasm Invasiveness | 1 | 1976 | 4054 | 0.000 |
Why?
|
| Mass Screening | 1 | 1976 | 1547 | 0.000 |
Why?
|
| Lymphatic Metastasis | 1 | 1976 | 4969 | 0.000 |
Why?
|
| Lung Neoplasms | 1 | 1983 | 12045 | 0.000 |
Why?
|